NCT04930159 (SISTER) is a NA clinical trial of Facilitated group support in Endometrial Cancer, sponsored by University of Washington.

Who is sponsoring NCT04930159?

NCT04930159 is sponsored by University of Washington.

What drugs are being tested in NCT04930159?

Interventions in NCT04930159: Facilitated group support, 1:1 Peer Support.

What condition does NCT04930159 study?

NCT04930159 studies Endometrial Cancer.

Is NCT04930159 still recruiting?

NCT04930159 is currently active, enrolled. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT04930159: SISTER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence

Active, enrolled NA Last updated 17 February 2026

What this trial tests

NA trial testing Facilitated group support in Endometrial Cancer in 252 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 September 2021

Primary endpoint
30 March 2026

31 October 2030

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	252
Start date	1 September 2021
Primary completion	30 March 2026
Estimated completion	31 October 2030
Sites	11 locations across United States

Drugs / interventions tested

Facilitated group support
1:1 Peer Support

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

University of Washington

Who can join

18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The SISTER study is a randomized trial, looking at various modalities of social support for Black patients undergoing treatment for endometrial cancer. There are three study arms: group support, 1:1 peer support, and enhanced usual care. The primary outcome is treatment completion, and the secondary outcome is social isolation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Study Protocol for the Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence (SISTER) study: a community engaged national randomized trial.
Oluloro A, Comstock B, Monsell SE, Gross M, et al · · 2024 · cited 7× · PMID 38348827 · DOI 10.57264/cer-2023-0159

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04930159 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04930159.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing